<< TechniScan awarded U.S. Patent for 3-D, Warm Bath Ultrasound system | Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED >>

ARCA biopharma regains compliance for continued listing on NASDAQ

Published on May 13, 2010 at 9:15 AM · No Comments

ARCA biopharma, Inc. (NASDAQ: ABIO), a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular disease, today announced that it received notification from the NASDAQ Stock Market that the Company has demonstrated compliance with the minimum stockholders' equity requirement for the NASDAQ Global Market set forth in Listing Rule 5450(b)(1)(A) and that ARCA is in compliance with all applicable requirements for continued listing on the NASDAQ Global Market.

Source ARCA biopharma

f6af19e0-93d2-4348-ab3b-d9d7cde6b994|0|.0

Posted in:

Tags: Cardiovascular Disease, Heart Failure

Sleep plays a crucial role in post-infarction remissionThe heart and the brain appear to be even more closely connected than previously imagined. The damag...
Grapes may prevent heart health risks beyond the simple blood pressure-lowering impactCan a grape-enriched diet prevent the downhill sequence of heart failure after years of high blood p...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.